Related Experiment Videos
Inhibiting tyrosine kinases: successes and limitations
1Department of Medicine, Vanderbilt-Ingram Cancer Center, Varderbilt University School of Medicine, Nashville, TN 37232-6307, US. carlos.orteaga@vanderbilt.edu
Abstract:
Seminal studies with STI-571 and Herceptin in chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer have clearly demonstrated that blockade of pathogenic tyrosine kinases can alter the natural history of appropriately selected human tumors. On the other hand, trials with EGF receptor inhibitors in unselected populations have shown anywhere from modest to no clinical activity. I will contrast below aspects in the development of inhibitors of Abl, c-Kit, HER2/neu (erbB2), and EGFR, highlight successes and pitfalls in this field, and propose some approaches for the future development of tyrosine kinase inhibitors in human cancer.
Insights
Targeted cancer therapies blocking specific tyrosine kinases show promise in selected patients. However, epidermal growth factor receptor inhibitors have limited success in broad populations, highlighting the need for refined strategies in tyrosine kinase inhibitor development.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted therapies inhibiting specific tyrosine kinases have revolutionized treatment for certain cancers.
- Successes with STI-571 (imatinib) and Herceptin (trastuzumab) demonstrate the potential of tyrosine kinase blockade.
- Epidermal Growth Factor Receptor (EGFR) inhibitors have shown limited efficacy in unselected patient groups.
Purpose of the Study:
- To contrast the development of inhibitors targeting Abl, c-Kit, HER2/neu (erbB2), and EGFR.
- To highlight key successes and challenges in the field of tyrosine kinase inhibitors (TKIs).
- To propose future directions for TKI development in human cancer therapy.
Main Methods:
- Review of seminal studies and clinical trial data for specific tyrosine kinase inhibitors.
- Comparative analysis of drug development pathways for different kinase targets.
- Discussion of patient selection criteria and treatment outcomes.
Main Results:
- Blockade of pathogenic tyrosine kinases (e.g., Abl, c-Kit, HER2/neu) can significantly alter the course of specific human tumors (e.g., CML, GIST, breast cancer).
- EGFR inhibitors have demonstrated modest to no clinical activity in unselected patient populations.
- Developmental successes and pitfalls vary significantly based on the targeted kinase and cancer type.
Conclusions:
- Targeted inhibition of specific tyrosine kinases is effective in molecularly selected cancers.
- Future TKI development requires careful consideration of target specificity, patient selection, and resistance mechanisms.
- Optimized strategies are crucial for maximizing the clinical benefit of TKIs in diverse human cancers.